Excessive accumulation of body fat triggers
insulin resistance and features of the
metabolic syndrome. Recently, evidence has accumulated that
obesity,
type 2 diabetes, and
metabolic syndrome are associated with reduced levels of serum
prolactin (PRL) in humans and rodents, raising the question of whether low PRL levels contribute to metabolic dysfunction. Here, we have addressed this question by investigating the role of PRL in
insulin sensitivity and adipose tissue fitness in obese rodents and humans. In diet-induced obese rats, treatment with PRL delivered via osmotic mini-pumps, improved
insulin sensitivity, prevented adipocyte
hypertrophy, and reduced inflammatory
cytokine expression in visceral fat. PRL also induced increased expression of Pparg and Xbp1s in visceral adipose tissue and elevated circulating
adiponectin levels. Conversely, PRL receptor null mice challenged with a high-fat diet developed greater
insulin resistance,
glucose intolerance, and increased adipocyte
hypertrophy compared with wild-type mice. In humans, serum PRL values correlated positively with systemic
adiponectin levels and were reduced in
insulin-resistant patients. Furthermore, PRL circulating levels and PRL produced by adipose tissue correlated directly with the expression of PPARG, ADIPOQ, and GLUT4 in human visceral and sc adipose tissue. Thus, PRL, acting through its cognate receptors, promotes healthy adipose tissue function and systemic
insulin sensitivity. Increasing the levels of PRL in the circulation may have therapeutic potential against
obesity-induced
metabolic diseases.